Merck Announces Third-Quarter 2016 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a...
View ArticleMerck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir)...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for...
View ArticleMerck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck...
View ArticleNew Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with...
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as...
View ArticleNew KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in...
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001...
View ArticleNew Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating...
View ArticleNew Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating...
View ArticleUpdated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show...
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS...
View ArticleKEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent,...
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH,...
View ArticleMerck to Acquire Afferent Pharmaceuticals
Dateline City: KENILWORTH, N.J. & SAN MATEO, Calif. KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent...
View ArticleMerck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in...
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH,...
View ArticleMerck Highlights Ongoing Commitment to Fighting Infectious Diseases with More...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more...
View ArticleMerck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and...
Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and...
View ArticleSystematic Review of 58 Publications of Real-World Use of GARDASIL® Presented...
Dateline City: KENILWORTH, N.J. Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),...
View ArticleResults of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor...
Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States...
View ArticleMerck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference...
View ArticleMerck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the...
Dateline City: KENILWORTH, N.J. Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1...
View ArticleMerck and Moderna Announce Strategic Collaboration to Advance Novel...
Dateline City: KENILWORTH, N.J. & CAMBRIDGE, Mass. Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch...
View ArticleMerck Animal Health Announces Agreement to Acquire Controlling Interest In...
Dateline City: MADISON, N.J. Manufacturer Offers Substantial Portfolio of Animal Vaccines in Latin America MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the...
View ArticleMerck Provides Regulatory Update on Biologics Licensing Application for...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration (FDA) has...
View ArticleMerck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical...
Dateline City: MADISON, N.J. Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United...
View ArticleData for Merck's Investigational Once-Daily Formulation of ISENTRESS®...
Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for...
View ArticleMerck Receives Breakthrough Therapy Designation from FDA and PRIME Status...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced two regulatory milestones for the company’s...
View ArticleMerck Announces Fourth-Quarter 2016 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a...
View ArticleMerck Announces Second-Quarter 2016 Financial Results
Dateline City: KENILWORTH, N.J. Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS...
View Article
